Brief: Cantargia - Reports Positive Results In Ongoing Phase IIa Clinical Trial

Cantargia AB

20/05/2021 06:43

May 20 (Reuters) - Cantargia AB  CANTA.ST :
    * ANNOUNCED ON WEDNESDAY POSITIVE RESULTS FROM THE ONGOING
CANFOUR
TRIAL INVESTIGATING NADUNOLIMAB (CAN04) IN COMBINATION WITH
GEMCITABINE/NAB-PACLITAXEL (ABRAXANE®) FOR FIRST LINE TREATMENT
OF PATIENTS WITH ADVANCED PANCREATIC CANCER (PDAC)
    * THE EFFICACY ANALYSIS INCLUDED 33 PATIENTS
    * OVERALL, THE EFFICACY COMPARES FAVORABLY TO HISTORICAL
CONTROL
DATA 
    * CURRENTLY, THE MEDIAN SURVIVAL IS 12.6 MONTHS WITH 58% OF
PATIENTS STILL ALIVE

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nWkr4fGYd3
    
 Further company coverage:  CANTA.ST  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))